

PRESS RELEASE

MONARCH THERAPEUTICS, INC.—AN ADOPTIVE CELL THERAPY COMPANY—EMERGES FROM STEALTH MODE AS A TECHNOLOGY SPINOUT OF THE UNIVERSITY OF PITTSBURGH

- Monarch Therapeutics, Inc. (“Monarch Therapeutics”) is launching with exclusive rights to University of Pittsburgh technology enabling the development of cell therapies
 - The universal cell therapy platform originates from the labs of Dr. Jason Lohmueller and Dr. Alexander Deiters at the University of Pittsburgh
 - Monarch Therapeutics will leverage its universal cell therapy platform to rapidly develop adoptive cell therapies with a focus on solid tumors including ovarian, breast, pancreatic, and kidney/renal cancers
-

PITTSBURGH, PA and PRINCETON, NJ, December 18, 2023— Monarch Therapeutics, Inc. (“Monarch Therapeutics”) today announces it is launching as an adoptive cell therapy company with a differentiated universal cell therapy platform that is set to provide innovative cell therapies to patients with solid tumors.

Monarch Therapeutics is led by an industry-veteran co-founder team having decades of experience developing cell therapies. Monarch Therapeutics is managed by Christopher Potts as President and CEO. Christopher is supported in launching Monarch Therapeutics by an experienced team including Dr. Nicholas Ostrout of Charles River Labs as Chief Business Advisor and Dr. Matt Hewitt also of Charles River Labs as Scientific Consultant. The core technology was developed at the University of Pittsburgh by Dr. Jason Lohmueller and Dr. Alexander Deiters, who combined have 35 years of experience in engineering new small molecule, protein, and cell functions. Monarch Therapeutics is a turnkey startup that is poised to rapidly progress pipeline candidates to the clinic.

Monarch Therapeutics is set to disrupt the solid tumor market with its highly versatile universal platform. The universal platform implements anti-tag CAR constructs to target and bind to a quiver of adaptor modalities that are engineered to target therapeutically relevant antigens. Monarch Therapeutics' novel adaptors are differentiated in the market as they provide unparalleled control and flexibility in designing therapies to overcome the challenges presented by solid tumor cancers.

“At Monarch Therapeutics our mission is to develop and deliver transformative, personalized therapies to patients – providing hope when battling the most difficult cancers. Armed with our universal platform, we are confident that we will rapidly deliver therapies to patients that are in need,” CEO, Christopher Potts. Dr. Jason Lohmueller of the University of Pittsburgh says, “these technologies will allow for targeting multiple cancers with a highly precise and multi-pronged attack, ultimately creating more effective therapies with enhanced safety.” Monarch Therapeutics is poised to develop world-class technology, and the teams to bring them to life, to provide hope to the many patients struggling with the most difficult diagnoses.



ABOUT MONARCH THERAPEUTICS

Monarch Therapeutics is an adoptive cell therapy company that is revolutionizing cell therapies. With a focus on solid tumors, Monarch Therapeutics implements its universal platform which works to eliminate tumors that are targeted by its differentiated adaptors that enable industry-leading tunability, multiplexing, and control. Monarch Therapeutics is set to drive multiple pipeline candidates through IND-enabling studies.

For Inquiries Please contact:
Monarch Therapeutics, Inc.
300 Witherspoon Street, Suite 201
Princeton, NJ 08542
info@monarchtherapeutics.com

-END-

